Treatment of NAFLD and NASH
View Patent ↗Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt.
1. A method for reducing cirrhosis or fibrosis in a subject having a disease that is non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH), comprising administering a therapeutically effective amount of seladelpar or a salt thereof to the subject.
2. A method for reducing cirrhosis or fibrosis in a subject having a disease that is non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH), comprising orally administering a therapeutically effective amount of seladelpar or a salt thereof to the subject.
3. The method of claim 2 where the daily dose of the seladelpar or a salt thereof administered to the subject is 20-200 mg, when the dose is calculated as seladelpar.
4. The method of claim 3 where the daily dose of the seladelpar or a salt thereof administered to the subject is 50-100 mg, when the dose is calculated as seladelpar.
5. The method of claim 2 where the seladelpar or a salt thereof is administered to the subject once/day.
6. The method of claim 2 where the disease is NAFLD.
7. The method of claim 6 where the cirrhosis or fibrosis is cirrhosis.
8. The method of claim 6 where the cirrhosis or fibrosis is fibrosis.
9. The method of claim 2 where the disease is NASH.
10. The method of claim 9 where the cirrhosis or fibrosis is cirrhosis.
11. The method of claim 9 where the cirrhosis or fibrosis is fibrosis.
12. A method for reducing cirrhosis or fibrosis in a subject having a disease that is non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH), comprising orally administering a therapeutically effective amount of seladelpar L -lysine dihydrate salt to the subject.
13. The method of claim 12 where the daily dose of the seladelpar L -lysine dihydrate salt administered to the subject is 20-200 mg, when the dose is calculated as seladelpar.
14. The method of claim 13 where the daily dose of the seladelpar L -lysine dihydrate salt administered to the subject is 50-100 mg, when the dose is calculated as seladelpar.
15. The method of claim 12 where the seladelpar L -lysine dihydrate salt is administered to the subject once/day.
16. The method of claim 12 where the disease is NAFLD.
17. The method of claim 12 where the disease is NASH.
18. The method of claim 12 where the cirrhosis or fibrosis is cirrhosis.
19. The method of claim 12 where the cirrhosis or fibrosis is fibrosis.